ClinicalTrials.gg
CompletedNCT02016560MCIUpdated Sep 22, 2020Results posted

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

A Phase 2/3 interventional study of florbetapir F 18 and Flortaucipir F18 in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 27 sites in United States. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-22.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2/3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
383
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
2nd of 22
383 · median 70
Started
2013
with 2 others
Phase 2/3
Only one
of the 22
Registered
2nd of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is the only one in phase 2/3, and was the 2nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).

Read the detailed description

This study was conducted in 2 phases: a Phase 2 Exploratory Phase and a Phase 3 Confirmatory Phase. An overarching goal of the Exploratory Phase of this protocol was to further investigate the pattern of flortaucipir PET imaging across the disease course, in cognitively healthy subjects through patients with cognitive decline. To accomplish this goal, the protocol investigated flortaucipir results in younger and older cognitively healthy normal volunteers and patients with clinical diagnoses for cognitive complaints, ranging from MCI to mild and moderate AD dementia. Additionally, the Exploratory Phase of this protocol investigated relationships between flortaucipir PET signal and cognitive decline over the 18-month study period.

The second, Confirmatory Phase of the study was designed to provide independent validation of the relationships observed in the exploratory analyses of the first phase. In particular, the goal of the second phase was to confirm the relationship between flortaucipir uptake in the brain as measured by PET signals at baseline and the subsequent rate of cognitive decline observed over the 18-month longitudinal follow up.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Exploratory Cognitively Healthy Subjects

  • ≥ 20 to ≤ 40 years of age OR ≥ 50 years of age
  • (MMSE) ≥ 29
  • No significant history of cognitive impairment

Exploratory MCI Subjects

  • ≥ 50 years of age
  • MMSE ≥ 24
  • Have MCI consistent with National Institute on Aging-Alzheimer's Association (NIA-AA) working group's diagnostic guidelines for AD
  • Have a study partner that can report on subject's activities of daily living

Exploratory AD Subjects

  • ≥ 50 years of age
  • MMSE > 10
  • Have possible or probable AD based on the NIA-AA working group's diagnostic guidelines for AD
  • Have a study partner that can report on subject's activities of daily living

Confirmatory Subjects

  • ≥ 50 years of age
  • MMSE ≥ 20 and ≤ 27
  • Cognitively impaired subjects with either MCI or dementia with a suspected neurodegenerative cause
  • Have a study partner that can report on subject's activities of daily living

Exclusion criteria

Exclusion Criteria:

  • Current psychiatric disease
  • Evidence of structural brain abnormalities
  • History of moderate or severe traumatic brain injury
  • Current clinically significant cardiovascular disease or abnormalities, or additional risk factors for Torsades de Pointes
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • History of alcohol or substance abuse or dependence
  • Females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have received or participated in a trial with medications in the past 30 days
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    Exploratory Cognitively Healthy Subjects

    Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.

    Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan

  • Experimental
    Exploratory MCI Subjects

    Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.

    Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan

  • Experimental
    Exploratory AD Subjects

    Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.

    Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan

  • Experimental
    Confirmatory Subjects

    Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.

    Drug: florbetapir F 18 · Drug: Flortaucipir F18 · Procedure: Brain PET Scan

Interventions

  • Also known as: Amyvid, 18F-AV-45

  • Also known as: T807, 18F-AV-1451

  • ProcedureBrain PET Scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline

    Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of boxes (CDR-SB) score over the follow-up period.

    Time frame: between baseline and 18 months

  2. Exploratory Phase: Cross-sectional Flortaucipir Imaging Results

    Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan

  3. Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status

    Assess the rate of change of tau deposition as measured by flortaucipir uptake (SUVr) over time. Change = 18 months SUVr - baseline SUVr.

    Time frame: baseline and 18 months

Secondary outcomes

  1. Confirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read

    This analysis used dichotomized CDR-SB change as a truth standard (1 point or more worsening = true positive vs. less than 1 point worsening = true negative) to assess the diagnostic performance of baseline Advanced AD tau status (τAD++) as determined by flortaucipir scan interpretation. Sensitivity and Specificity were calculated for each of the 5 independent imaging readers. Sensitivity is the percentage of true positive cases correctly identified by an Advanced AD pattern scan. Specificity is the percentage of true negative cases correctly identified by scans that were not classified as Advanced AD pattern.

    Time frame: baseline and 18 months

  2. Exploratory Phase: Correlation Between Flortaucipir SUVr and Age

    Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan

07

Results

Posted Aug 24, 2020

Participant flow

Exploratory cohort subjects were enrolled starting in Dec 2013. Confirmatory cohort subjects were enrolled Dec 2014-July 2017. Exploratory cohort subjects were not eligible for the confirmatory phase.

Exploratory Phase
Participant flow — Exploratory Phase
MilestoneExploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects AD
Started1658985100
Completed1654623500
Not completed04361600
Confirmatory Phase
Participant flow — Confirmatory Phase
MilestoneExploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects AD
Started00009862
Completed00007635
Not completed00002227

Outcome measures

PrimaryConfirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline

Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of boxes (CDR-SB) score over the follow-up period.

Time frame:
between baseline and 18 months
Reported as:
Count of participants · Participants
Confirmatory Phase: Relationship Between Neocortical Flortaucipir Uptake and the Subsequent Rate of Cognitive Decline
ParticipantsPredicted to ProgressNot Predicted to Progress
Clinically meaningful progression3631
Did Not Progress2737
Statistical analysis
  • Predicted to Progress vs Not Predicted to Progress · Cox proportional hazards · p = 0.067 (A p-value of \<0.05 was the a priori threshold for statistical significance.) · Cox proportional hazard: 1.581 · 95% CI 0.968 to 2.581The Cox proportional hazard model was adjusted for baseline age, American National Adult Reading Test (ANART) score, and baseline CDR-SB score.
PrimaryExploratory Phase: Cross-sectional Flortaucipir Imaging Results

Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan
Reported as:
Least squares mean · standardized uptake value ratio (SUVr)
Exploratory Phase: Cross-sectional Flortaucipir Imaging Results
standardized uptake value ratio (SUVr)Exploratory AD SubjectsExploratory MCI SubjectsExploratory Older Cognitively Healthy SubjectsExploratory Young Cognitively Healthy Subjects
Aβ+ SUVr1.53 ± 0.0371.26 ± 0.0301.08 ± 0.093—
Aβ- SUVr1.03 ± 0.0510.99 ± 0.0290.98 ± 0.0291.01 ± 0.039
Statistical analysis
  • Exploratory AD Subjects vs Exploratory Older Cognitively Healthy Subjects · ANCOVA · p = <0.0001 (No adjustment for multiple comparisons. No a priori threshold was set.)Adjusted for age
  • Exploratory MCI Subjects vs Exploratory Older Cognitively Healthy Subjects · ANCOVA · p = 0.0622 (No adjustment for multiple comparisons. No a priori threshold was set.)Adjusted for age
  • Exploratory AD Subjects vs Exploratory MCI Subjects · ANCOVA · p = <0.0001 (No adjustment for multiple comparisons. No a priori threshold was set.)Adjusted for age
PrimaryExploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status

Assess the rate of change of tau deposition as measured by flortaucipir uptake (SUVr) over time. Change = 18 months SUVr - baseline SUVr.

Time frame:
baseline and 18 months
Reported as:
Least squares mean · standardized uptake value ratio (SUVr)
Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status
standardized uptake value ratio (SUVr)Exploratory AB+ (Amyloid Beta Positive)Exploratory AB- (Amyloid Beta Negative)
Exploratory Phase: Longitudinal Change in Tau Deposition Over Time, by Amyloid Status0.052359 ± 0.0085360.000655 ± 0.002394
Statistical analysis
  • Exploratory AB+ (Amyloid Beta Positive) · Mixed Models Analysis · p = <0.0001
  • Exploratory AB- (Amyloid Beta Negative) · Mixed Models Analysis · p = 0.7851
SecondaryConfirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read

This analysis used dichotomized CDR-SB change as a truth standard (1 point or more worsening = true positive vs. less than 1 point worsening = true negative) to assess the diagnostic performance of baseline Advanced AD tau status (τAD++) as determined by flortaucipir scan interpretation. Sensitivity and Specificity were calculated for each of the 5 independent imaging readers. Sensitivity is the percentage of true positive cases correctly identified by an Advanced AD pattern scan. Specificity is the percentage of true negative cases correctly identified by scans that were not classified as Advanced AD pattern.

Time frame:
baseline and 18 months
Reported as:
Number · percentage of cases correctly identified
Confirmatory Phase: Diagnostic Performance of Flortaucipir Visual Read
percentage of cases correctly identifiedIndependent Readers
Reader 1 Sensitivity59.6 (46.1 to 71.8)
Reader 1 Specificity65.5 (52.7 to 76.4)
Reader 2 Sensitivity53.8 (40.5 to 66.7)
Reader 2 Specificity65.5 (52.7 to 76.4)
Reader 3 Sensitivity55.8 (42.3 to 68.4)
Reader 3 Specificity65.5 (52.7 to 76.4)
Reader 4 Sensitivity59.6 (46.1 to 71.8)
Reader 4 Specificity65.5 (52.7 to 76.4)
Reader 5 Sensitivity50.0 (36.9 to 63.1)
Reader 5 Specificity65.5 (52.7 to 76.4)
Statistical analysis
  • Independent Readers ·
SecondaryExploratory Phase: Correlation Between Flortaucipir SUVr and Age

Flortaucipir standardized uptake value ratio (SUVr). A value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan
Reported as:
Mean · standardized uptake value ratio (SUVr)
Exploratory Phase: Correlation Between Flortaucipir SUVr and Age
standardized uptake value ratio (SUVr)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy Subjects 50-59Exploratory Older Cognitively Healthy Subjects 60-69Exploratory Older Cognitively Healthy Subjects 70-79Exploratory Older Cognitively Healthy Subjects >=80
Exploratory Phase: Correlation Between Flortaucipir SUVr and Age1.0083 ± 0.039051.0203 ± 0.036931.0110 ± 0.041491.0010 ± 0.026041.0048 ± 0.03978
Statistical analysis
  • Exploratory Young Cognitively Healthy Subjects vs Exploratory Older Cognitively Healthy Subjects 50-59 vs Exploratory Older Cognitively Healthy Subjects 60-69 vs Exploratory Older Cognitively Healthy Subjects 70-79 vs Exploratory Older Cognitively Healthy Subjects >=80 · Pearson · p = 0.4361 · Pearson's correlation coefficient: -0.0925

Adverse events

Collected over Adverse events (AEs) were collected at scan visits, regardless of attribution to study drug. End of study for AE reporting was 48 hours after the last study drug administration. AEs occurring after study drug administration, but outside that window were not recorded, unless considered attributable to either drug.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Exploratory Younger Cognitively Healthy Subjects0/16 (0%)0/16 (0%)3/16 (18.8%)
Exploratory Older Cognitively Healthy Subjects0/58 (0%)0/58 (0%)17/58 (29.3%)
Exploratory MCI Subjects0/98 (0%)1/98 (1%)21/98 (21.4%)
Exploratory AD Subjects0/51 (0%)0/51 (0%)13/51 (25.5%)
Confirmatory Subjects MCI0/98 (0%)0/98 (0%)13/98 (13.3%)
Confirmatory Subjects AD0/62 (0%)0/62 (0%)0/62 (0%)
Most frequent serious events
Most frequent serious events
EventExploratory Younger Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects AD
angina pectorisCardiac disorders0/160/581/980/510/980/62
Most frequent other events
Showing 10 of 42
Most frequent other events
EventExploratory Younger Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects AD
Injection site painGeneral disorders0/165/588/982/516/980/62
Abdominal painGastrointestinal disorders1/160/580/980/510/980/62
Frequent bowel movementsGastrointestinal disorders1/160/580/980/510/980/62
ParaesthesiaNervous system disorders1/160/581/980/510/980/62
DizzinessNervous system disorders1/160/580/980/512/980/62
Head discomfortNervous system disorders1/160/580/980/510/980/62
HeadacheNervous system disorders0/163/583/981/514/980/62
HypertensionVascular disorders0/161/580/982/510/980/62
FatigueGeneral disorders0/162/581/980/510/980/62
Blood pressure increasedInvestigations0/162/582/981/510/980/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects ADTotal
Mean28.9 ± 4.8868.5 ± 10.2970.8 ± 9.373.9 ± 9.01——67.9 ± 14.36
Age, Continuous
Age, Continuous(years)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects ADTotal
Mean————72.5 ± 9.6973.6 ± 9.5372.9 ± 9.61
Sex: Female, Male
Sex: Female, Male(Participants)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects ADTotal
Female72649284430184
Male93249235432199
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects ADTotal
Hispanic or Latino11405415
Not Hispanic or Latino155794519358368
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects ADTotal
Asian1110115
Black or African American39723024
White114789479461349
American Indian or Alaska Native0001001
Native Hawaiian or Other Pacific Islander0000000
Other1111004
Clinical Dementia Rating - Sum of Boxes (CDR-SB)
Clinical Dementia Rating - Sum of Boxes (CDR-SB)(units on a scale)Exploratory Young Cognitively Healthy SubjectsExploratory Older Cognitively Healthy SubjectsExploratory MCI SubjectsExploratory AD SubjectsConfirmatory Subjects MCIConfirmatory Subjects ADTotal
Mean————2.8 ± 1.734.3 ± 1.693.4 ± 1.88
08

Study locations

27 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Four Peaks Neurology
    Scottsdale, Arizona 85258, United States
  • Mayo Clinic
    Scottsdale, Arizona 85259, United States
  • Banner Sun Health Research Institute
    Sun City, Arizona 85351, United States
  • UC Irvine
    Irvine, California 92697, United States
  • Hoag Memorial
    Newport Beach, California 92663, United States
  • Norther California PET Imaging Center
    Sacramento, California 95816, United States
  • UC Davis
    Sacramento, California 95817, United States
  • UC San Francisco
    San Francisco, California 94158, United States
  • Neurological Research Institute
    Santa Monica, California 90404, United States
  • Molecular NeuroImaging
    New Haven, Connecticut 06510, United States
  • Quantum Laboratories
    Deerfield Beach, Florida 33064, United States
  • 21st Century Oncology
    Fort Myers, Florida 33912, United States
  • Sandlake Imaging
    Orlando, Florida 32806, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • USF Health Byrd Alzheimer's Center
    Tampa, Florida 33613, United States
  • Independent Imaging
    West Palm Beach, Florida 33407, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Boston University
    Boston, Massachusetts 02118, United States
  • Alzheimer's Disease Center
    Quincy, Massachusetts 02169, United States
  • Center for Clinical Imaging Research
    Saint Louis, Missouri 63110, United States
  • Las Vegas Radiology
    Las Vegas, Nevada 89147, United States
  • Center for Brain Health - NYU Langone Medical Center
    New York, New York 10016, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Butler Hospital
    Providence, Rhode Island 02906, United States
09

References and documents

Publications

  • Lu M, Pontecorvo MJ, Devous MD Sr, Arora AK, Galante N, McGeehan A, Devadanam C, Salloway SP, Doraiswamy PM, Curtis C, Truocchio SP, Flitter M, Locascio T, Devine M, Zimmer JA, Fleisher AS, Mintun MA; AVID Collaborators. Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. JAMA Neurol. 2021 Apr 1;78(4):445-453. doi: 10.1001/jamaneurol.2020.5505. PubMed 33587110 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Jul 2017, 43 months.

Results were first posted in Aug 2020, 3 years after primary completion. A results delay was requested in Jul 2018.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 43 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2013
First posted
Dec 20, 2013
StartActual
Dec 2013
Primary completionActual
Jul 28, 2017
CompletionActual
Jul 28, 2017
Results delay requested
Jul 20, 2018
Results first posted
Aug 24, 2020
Last update
Sep 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02016560
Responsible party
Sponsor
First posted
Dec 20, 2013
Start date
Dec 2013
Primary completion
Jul 28, 2017
Completion
Jul 28, 2017
Results posted
Aug 24, 2020
Last update
Sep 22, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion